단계 미표기완료
A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
연구 개요
The purpose of this study is to evaluate the safety by assessing all serious and non-serious adverse events (AEs), irrespective of relatedness or expectedness, as well as other safety parameters including laboratory values, serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not reflected on the precaution in the use, ADRs already known, non-serious ADRs and other safety related information (laboratory values changes, etc).
- 스폰서
- 리드: 셀트리온
- 적응증
- Essential Hypertension
- 목표 등록
- 718명
- 시작일
- 2019-09-11
- 완료(예정)
- 2023-05-25
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.